

UCLA

UCLA Previously Published Works

Title

TNF α in Liver Fibrosis

Permalink

<https://escholarship.org/uc/item/91x7w6q8>

Journal

Current Pathobiology Reports, 3(4)

ISSN

2167-485X

Authors

Yang, Yoon Mee

Seki, Ekihiro

Publication Date

2015-12-01

DOI

10.1007/s40139-015-0093-z

Peer reviewed



HHS Public Access

Author manuscript

Curr Pathobiol Rep. Author manuscript; available in PMC 2016 December 01.

Published in final edited form as:

Curr Pathobiol Rep. 2015 December ; 3(4): 253–261. doi:10.1007/s40139-015-0093-z.

TNF α in liver fibrosis

Yoon Mee Yang, Ph.D. and Ekihiro Seki, M.D., Ph.D.

Department of Medicine, Division of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA

Yoon Mee Yang: Janice.Yang@cshs.org; Ekihiro Seki: Ekihiro.Seki@cshs.org

Abstract

Hepatocyte death, inflammation, and liver fibrosis are the hallmarks of chronic liver disease. Tumor necrosis factor- α (TNF α) is an inflammatory cytokine involved in liver inflammation and sustained liver inflammation leads to liver fibrosis. TNF α exerts inflammation, proliferation, and apoptosis. However, the role of TNF α signaling in liver fibrosis is not fully understood. This review highlights the recent findings demonstrating the molecular mechanisms of TNF α and its downstream signaling in liver fibrosis. During the progression of liver fibrosis, hepatic stellate cells play a pivotal role in a dynamic process of production of extracellular matrix proteins and modulation of immune response. Hepatic stellate cells transdifferentiate into activated myofibroblasts in response to damaged hepatocyte-derived mediators and immune cell-derived cytokines/chemokines. Here, we will discuss the role of TNF α in hepatic stellate cell survival and activation and the crosstalk between hepatic stellate cells and hepatocytes or other immune cells, such as macrophages, dendritic cells, and B cells in the development of liver fibrosis.

Keywords

Liver fibrosis; TNF α ; hepatic stellate cell; hepatocyte; macrophage

Introduction

Cirrhosis is the advanced stage of liver fibrosis. It causes over 1 million deaths per year, being the 14th leading cause of death worldwide [1]. Liver fibrosis is characterized by the excessive deposition of extracellular matrix (ECM) proteins (e.g. collagen, elastin, and fibronectin), which is a result of hepatocyte death and subsequent liver inflammation [2]. The pathogenesis of liver fibrosis orchestrates the complex interplay of various hepatic cells including hepatocytes, Kupffer cells and hepatic stellate cells (HSCs). HSCs and portal fibroblasts are the major sources of myofibroblasts in the liver, which are involved in production of ECM proteins, ECM degradation, hepatic wound healing, tissue scarring,

Correspondence to: Dr. Ekihiro Seki, Street addresses: 8700 Beverly Blvd., DAVIS, Suite 2099, Los Angeles, CA 90048, USA, Phone numbers: 310-423-6605, Fax numbers: 310-423-0653.

Conflict of Interest

Yoon Mee Yang and Ekihiro Seki declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

fibrosis, and remodeling [3]. A recent fate-tracing study demonstrated that HSCs are the major contributors to liver fibrosis among candidate cellular sources for hepatic myofibroblasts [4]. Hepatocyte death is associated with the development of liver fibrosis, as proven by the fact that mice with specific deletion of anti-apoptotic genes, such as Bcl-xl or Mcl-1, in hepatocytes developed spontaneous hepatocyte apoptosis and liver fibrosis [5, 6]. The apoptosis and/or necrosis of the parenchymal cells may contribute to the activation of HSCs as well as liver macrophages. Activated HSCs and liver resident macrophages recruit other immune cells such as circulating monocytes, T cells and neutrophils by secretion of pro-inflammatory mediators [7].

Tumor necrosis factor- α (TNF α) is a pleiotropic cytokine produced by a variety of immune cells including macrophages/monocytes. TNF α can trigger multiple signaling pathways involved in inflammation, proliferation, and apoptosis. Although TNF α has been implicated in the pathogenesis of chronic liver inflammation that leads to liver fibrosis, the role of TNF α in liver fibrosis has not been fully characterized. The inflammatory phase is perpetuated by TNF α production, which results in the activation of resident HSCs into fibrogenic myofibroblasts. The TNF receptor 1 (TNFR1) knockout mice showed reduced carbon tetrachloride (CCl₄)-induced liver fibrosis [8]. It is no doubt that TNF α can promote fibrosis. However, TNF α is also known to suppress collagen α 1(I) gene expression in culture fibroblasts [9]. This review will summarize the current available knowledge of the role of TNF α signaling in liver fibrosis.

TNF α Signaling

TNF α is synthesized as a 26 kDa membrane bound precursor form which is cleaved into its soluble mature form (17 kDa) by TNF α -converting enzyme (TACE) [10]. Both precursor and soluble form of TNF α can transmit their downstream signal through binding to TNFR1 while TNFR2 is preferentially activated by the precursor form [11]. These two types of TNF receptor exert separate or overlapping downstream signal cascades. TNFR1 contains a death domain in the cytoplasmic tail whereas TNFR2 lacks this motif [12, 13]. Trimeric TNF α binding to TNFR1 leads to the receptor trimerization that forms Complex I by recruiting TNFR1-associated death domain protein (TRADD), receptor interacting kinase 1 (RIP1), and several E3 ligases, such as TNF-receptor-associated factor 2 and 5 (TRAF2/5), cellular inhibitor of apoptosis 1/2 (cIAP1/2), and dimeric linear ubiquitin chain assembly complex (LUBAC) [14, 15]. In the Complex I, the Lys63 (K63)-linked polyubiquitination of RIP1 by cIAPs induces the recruitment of the transforming growth factor β (TGF- β)-activated kinase 1 (TAK1)-TAK1-binding protein 1 (TAB1)-TAB2/TAB3 complex. TAK1 binds to RIP1 polyubiquitin chains through TAB2 [16], which is required to recruit the I κ B kinase (IKK) complex containing two catalytic α and β subunits, and a regulatory γ subunit, also known as NF- κ B essential modulator (NEMO) [17]. Activated TAK1 phosphorylates IKK β , which in turn leads to phosphorylation and degradation of I κ B α . Ultimately, NF- κ B homo- or heterodimers released from NF- κ B-I κ B α complex is translocated into nucleus, followed by the regulation of gene transcription [18]. Phosphorylated TAK1 also activates MAPK pathways by the phosphorylation-dependent manner [19, 20]. In addition, TRAF2 and RIP1 are required for TNFR1-mediated c-Jun N-terminal Kinase (JNK) activation [21]. A20- and cylindromatosis (CYLD)-mediated deubiquitylation of Complex I components induces

disassembly of Complex I. Subsequently either cytosolic Complex IIa or Complex IIb is formed [22]. Complex IIa comprises TRADD, Fas-associated death domain protein (FADD), caspase-8 and RIP1, which mediates activation of caspase cascades, leading to apoptosis [23]. When caspase-8 or FADD is inhibited, Complex IIb consisting of RIP1 kinase and RIP3 is formed, which mediates necroptosis (Figure 1) [24–26]. TNFR2 does not bind to TRADD and FADD, but directly interacts with TRAF2, which in turn recruits TRAF1 [14].

TNF α Signaling in Liver Fibrosis

TACE

TACE cleaves pro-TNF α between Ala76 and Val77, which releases a bioactive soluble 17kDa TNF α . In the diet-induced non-alcoholic steatohepatitis (NASH) models (choline-deficient L-amino acid defined [CDAA] diet and western diet supplemented with high fructose), TACE activity is increased with a concomitant increase in TNF α production and fibrogenic transcripts, such as collagen, α -smooth muscle actin (α -SMA) and TGF- β [27]. Elevated advanced glycation endproducts in diabetic patients may upregulate TACE activity, leading to the progression of NASH through TNF α as well as its multiple target cytokines/chemokines [27].

TNF α

Macrophages play a crucial role in the development of liver fibrosis. HSCs cocultured with hepatic macrophages showed a similar gene expression pattern to *in vivo*-activated HSCs isolated either from bile duct-ligated or CCl₄-treated mice [28]. Macrophage depletion resulted in the attenuation of liver fibrosis [29–31]. Hepatic macrophages profoundly activated NF- κ B signaling pathways in HSCs as mediated by TNF α and interleukin-1 (IL-1) [28]. Macrophage-derived TNF α and IL-1 enhanced the survival of HSCs, but had no effect on HSC activation [28].

TNF Receptors

To evaluate the specific involvement of TNF receptors, TNFR1 and TNFR2, in liver fibrosis, genetic modified animals were used [32]. During the 7-day culture activation, the induction of procollagen- α 1(I) mRNA levels were inhibited in HSCs isolated from TNFR1 knockout or TNFR1/R2 double knockout (TNFR-DKO) mice, but not from TNFR2 knockouts, indicating that TNFR1, but not TNFR2, is involved in HSC activation [32]. TNFR1 also participates in HSC proliferation elicited by platelet-derived growth factor (PDGF) [32]. Given that PDGF-induced Akt phosphorylation is diminished by knockdown of the p65 subunit of NF- κ B (a downstream of TNFR1), a crosstalk between PDGF and TNFR1 receptors may play a role [32]. TNF α can induce matrix metalloproteinase-9 (MMP9) production through TNFR1 in an NF- κ B-dependent manner, which may contribute to remodeling of ECM [32]. In mouse liver fibrosis model induced by CCl₄, dimethylnitrosamine, or bile duct ligation, TNFR1 knockout mice showed reduced liver damage and fibrosis, demonstrating the contribution of TNFR1 in liver fibrosis [32–34]. In addition, TNFR-DKO mice had attenuated liver fibrosis in NASH induced by methione-

choline-deficient (MCD) diet [35]. Taken together, TNFR1, but not TNFR2, is important for liver fibrosis development.

Alcoholic hepatitis is characterized by the presence of hepatocellular damage, steatosis and pericellular fibrosis. The microarray transcriptomic analysis of patients with alcoholic hepatitis compared to healthy individuals showed that several TNF superfamily receptors, but not ligands, were upregulated in alcoholic hepatitis patients [36]. Among them, Fn14, the receptor for TNF-like weak inducer of apoptosis (TWEAK), is solely overexpressed in alcoholic hepatitis patients, but not in patients with chronic hepatitis C or NASH [36]. Fn14 is mainly expressed in the parenchymal cells around the areas of fibrosis in patients with alcoholic hepatitis [36]. When high precision-cut mouse liver slices were treated with TGF- β , Fn14 expression was enhanced [36]. These findings suggest that a TNF family member TWEAK and its receptor Fn14 may participate in alcohol-induced liver fibrosis.

TAK1

TAK1, a MAP3K family member, is activated *via* TNFR1 as well as IL-1, TGF- β , and Toll-like receptors (TLRs) [37]. Mice with deletion of TAK1 in hepatocytes developed spontaneous hepatocyte death, inflammation, and liver fibrosis, starting as early as the age of 1 month [38]. TNF α -induced JNK and NF- κ B activation is diminished in primary hepatocytes from Tak1^{fllox/fllox}/Alb-Cre (*Tak1* HEP) mice [38]. Deletion of TNFR1 or TGF- β R2 in *Tak1* HEP mice ameliorated liver fibrosis, indicating that TNF α and TGF- β receptor signaling drive spontaneous liver fibrosis in the setting of TAK1 inactivation [38, 39]. Spontaneous liver injury and subsequent inflammation in *Tak1* HEP mice were caused by Kupffer cell-derived TNF α and TGF- β 1, leading to HSC activation and liver fibrosis [38]. TNF α and TGF- β -mediated hepatocyte damage further activated Kupffer cell/macrophages and induced the inflammatory cytokine production in *Tak1* HEP mice [39].

CYLD

The tumor suppressor CYLD, a deubiquitinating enzyme, deactivates TNF α -induced NF- κ B or JNK signaling by TAK1 inactivation through cleavage of K63-linked polyubiquitin chains [40–45]. Deletion of CYLD exon 9 causes the truncation and inactivation of the carboxyl-terminal deubiquitinating domain of CYLD, which were found in human skin appendage tumors [46]. Liver-specific deletion of CYLD exon9 (CYLD^{lox/lox}/ALFP-Cre) induces spontaneous apoptosis of periportal hepatocyte, and subsequent HSC and Kupffer cell activation, thereby triggering fibrosis, inflammation, and TNF α production [46, 47]. In these mice, TNFR1 is required for the expansion of hepatocyte death toward central veins [47]. The expression of the naturally occurring short-CYLD splicing variant is increased in the mice with liver-specific deletion of CYLD exon7/8 (CYLD^{fllox/fllox}/Alb-Cre) [48]. These mice developed severe biliary damage, cholestatic liver fibrosis, and ultimately liver cancer [48].

In fibrotic septa of cirrhotic human liver tissues [49], co-localization of CYLD with α -SMA was observed. During *in vitro* HSC activation, CYLD expression is increased, which is further upregulated in response to TNF α [49]. In addition to TNF α , CYLD also plays an important role in regulation of hepatocyte growth factor (HGF) expression. CYLD can

interact with HDAC7 in the cytoplasm of HSC, which enhances removal of HDAC7 from the HGF promoter to increase HGF gene transcription. This transcriptional regulation of HGF is independent of the deubiquitinating activity of CYLD [49]. Thus, CYLD also contributes to amelioration of liver injury and fibrosis through HGF transcriptional regulation [49]. These findings all support the importance of CYLD in chronic liver disease.

Liver biopsy specimens from cirrhotic patients showed that, in CD14⁺ macrophages, CYLD levels negatively correlated with the levels of the cytoplasmic Notch intracellular domain (NICD), a marker for Notch activation [50]. In macrophages, CYLD expression is negatively regulated by recombinant signal binding protein J κ (RBP-J), the main transcription factor of Notch receptor signaling. CYLD plays a role in Notch-RBP-J-mediated liver fibrosis by inhibiting NF- κ B activation [50].

JNK

JNK pathway has been implicated in TNF α -mediated liver injury [51]. Recent studies have shown the cell-type-specific functions of JNK in liver pathophysiology. Hepatocyte-derived JNK1 is believed crucial for TNF α -induced hepatocyte apoptosis [52], but is less important in liver fibrosis [53]. JNK activation was observed in the myofibroblasts of human fibrotic/cirrhotic livers [53]. Disruption of JNK1 in primary HSCs inhibited their transdifferentiation into myofibroblasts but induced cell death [53]. The *in vivo* role of HSC-derived JNK1 in the development of liver fibrosis should be reevaluated by using Lrat-Cre mice. In non-stress condition, JNK1 and JNK2 upregulate α -SMA levels in HSCs, but only JNK1 participates in α -SMA upregulation under stress condition induced by TGF- β during liver fibrosis [54]. JNK1 in bone marrow-derived cells contributes to the development of chronic liver inflammation and carcinogenesis [55]. Intriguingly, JNK1 in Kupffer cells promotes CDAA diet-induced liver fibrosis by inducing inflammatory and fibrogenic mediators [56]. However, in CCl₄ and bile duct ligation-induced mouse liver fibrosis, JNK1 in bone marrow-derived cells does not play a role [53].

NF- κ B

An NF- κ B decoy, a synthetic oligodeoxynucleotide imitating the NF- κ B binding site, has potential to suppress CCl₄-induced liver fibrosis, through its anti-inflammatory effects on hepatic macrophages [57]. In primary rat hepatocytes, IKK β is mainly involved in TNF α -induced NF- κ B activation whereas IKK α has a minimal effect. Surprisingly, hepatocyte-specific IKK β knockout mice did not show the high susceptibility to lipopolysaccharide (LPS)-induced fulminant hepatitis, even though LPS is a strong inducer of TNF α [58]. However, these mice were highly susceptible to concanavalin A-induced liver injury through the membrane-bound form of TNF α , but not by the circulating free TNF α [58]. Hepatocyte-specific deletion of RelA/p65 or NEMO sensitized hepatocytes to TNF α -induced apoptosis [59, 60]. Interestingly, mice with hepatocyte-specific deletion of NEMO developed spontaneous chronic hepatitis, steatosis, liver fibrosis, and HCC [60]. Crossing hepatocyte-specific NEMO knockout mice with TNFR1^{-/-} mice decreased liver fibrogenesis, whereas deletion of TNFR1 in hematopoietic cells enhanced acute and chronic liver injury, suggesting that TNFR1 in hepatocytes and immune cells have opposite roles in liver injury in hepatocyte-specific NEMO knockout mice [61].

RIP1 and RIP3

TNF α -mediated rapid formation of Complex I participates in proinflammatory and anti-apoptotic NF- κ B pathways. Subsequently, the Complex IIa (consisting of TRADD, FADD and pro-caspase-8) is formed and mediates TNF α -mediated apoptosis. Alternatively, necroptosis, a programmed necrosis regulated by RIP1 and RIP3 downstream of TNF receptor, is induced through formation of Complex IIb [24–26] when caspase-8 or FADD is inhibited [62]. The treatment of concanavalin A that induces T cell-mediated liver injury increased necrotic liver injury in hepatocyte-specific caspase-8 knockout mice [62]. Hepatocyte-specific caspase-8 and NEMO double-knockout mice showed massive liver necrosis and cholestasis [62]. Caspase-8 deletion inhibited proteolytic cleavage of RIP1, resulting in the formation of FADD-RIP1–RIP3 kinase complexes required for the programmed necrosis and premature activation of NF- κ B and JNK [62, 63]. RIP3 is overexpressed in the livers of human NASH patients and MCD diet-fed mice [64]. RIP3-dependent necroptosis accelerates NASH-induced liver fibrosis through a positive feedback loop between RIP3 and JNK, but it has no effect on CCl₄-induced liver fibrosis [64]. Thus, RIP1- or RIP3-dependent necroptosis may promote non-apoptotic liver injury and may contribute to the transition from simple fatty liver to NASH, but does not play a role in toxin-induced liver fibrosis [62, 64].

Role of TNF α in HSCs and other liver cells

HSCs

HSCs constitute ~15% of the resident cell population in normal liver [65]. A novel fate-tracing strategy suggested that HSCs are the primary cells that contribute to liver fibrosis among the various cellular sources that differentiate into myofibroblasts [4]. HSCs can be activated by stimulation with inflammatory and fibrogenic cytokines. The contribution of TNF α in HSC activation and liver fibrosis has been reported in several papers [9, 66–68]. However, their conclusions were mixed. One hand, TNF α treatment suppressed collagen α 1 gene expression, apoptosis, and proliferation in activated HSC *in vitro* [9, 66]. On the other hand, TNF α upregulated both matrix metalloproteinases and a tissue inhibitor of metalloproteinase-1 (TIMP1) expression of HSCs [67]. Cholestasis-induced TNF α production might be involved in liver fibrosis progression through TIMP1 induction from HSCs [68]. Furthermore, TNFR1 deficiency inhibited PDGF-induced HSC proliferation, procollagen- α 1 expression, and TNF α -induced MMP9 and TIMP1 expression [32]. A recent study demonstrated that TNF α and IL-1 contribute to liver fibrosis through NF- κ B-dependent HSC survival rather than myofibroblastic activation [28]. TNF α has pleiotropic effects on HSCs, but overall TNF α is suggested to promote liver fibrosis through its pro-survival effect.

Hepatocytes

Hepatocyte death is the initial event to drive liver inflammation and fibrosis [69]. The proapoptotic stimuli, such as FasL and TRAIL, induce hepatocyte apoptosis. Apoptotic bodies are engulfed by HSC and Kupffer cells, which induce the upregulation of profibrogenic factors (e.g., TGF- β) and death ligands (e.g., TNF α) [70]. Chronic activation of HSC and Kupffer cells further accelerates hepatocyte death and hepatic inflammation,

creating a feedforward loop [70, 71]. TNF α triggers the extrinsic cell death pathway *via* the caspase cascade, but it also affects survival pathway *via* NF- κ B activation [69]. TNF α injection alone does not induce hepatocyte death *in vivo*. However, in combination with the inhibition of canonical NF- κ B signaling, TNF α induces hepatocyte death and acute liver failure [60, 72]. Hepatitis C virus infection also triggers TNF α -induced cell death through NF- κ B inhibition [73]. In addition, LPS injection potentiates TNF α production and accelerates TNF α -induced hepatocyte apoptosis in fatty liver mice induced by MCD diet feeding [74]. Multiple LPS injection also enhances the development of liver fibrosis in MCD-fed mice [74]. Although the underlying mechanism remains to be elucidated, enhanced TNF α -induced hepatocyte apoptosis may be involved in LPS-mediated liver fibrosis in fatty liver disease.

Hence, the dynamic interplay between hepatocytes and activated HSCs through secreted mediators may be involved in the development of liver fibrosis. TNF α treatment induces production of periostin, a secretory profibrogenic protein, in HepG2 cells [75]. Fibroblasts treated with a supernatant collected from TNF α -treated HepG2 cells have increased type 1 collagen expression, which may be through periostin. Moreover, TNF α and IL-17 co-treatment synergistically increase periostin through c-Jun and STAT-3, respectively. Recently, a novel cytokine IL-32 was identified to play a role in HCV-related liver inflammation and fibrosis [76]. The study found a positive correlation between TNF α and IL-32 in hepatitis C patients and increased IL-32 expression in HCV replicating Huh7.5 cells treated with TNF α . These data support the role of TNF α in IL-32-associated HCV infection and its related fibrosis [76].

Macrophages

Activation of hepatic macrophages promotes the development of liver fibrosis through secretion of proinflammatory cytokines and chemokines that activate HSC. CD68⁺ cells (abundantly expressed in monocytes and macrophages including hepatic resident Kupffer cells) undergo apoptosis in dimethylnitrosamine-induced liver fibrosis in rats [77]. CD68⁺/TNF α ⁺ cells reside close to α -SMA⁺ HSCs in hepatic lobules [77]. Hepatic macrophage-derived TNF α contributes to NF- κ B-dependent HSC survival, thereby promoting liver fibrosis [28]. However, hepatic macrophages seem no effect on myofibroblastic activation in HSC [28].

It has been reported that chemokines and their receptors participate in the development of liver fibrosis. For example, C-C motif chemokine receptor (CCR) 9⁺ macrophages play an important role in the pathogenesis of liver fibrosis [78]. Among mononuclear liver cells, TNF α -producing CCR9⁺ cells are infiltrated in acute liver injury induced by CCl₄. CCR9 knockout mice showed protection against CCl₄-induced liver fibrosis. TNF α neutralization using anti-TNF α antibody inhibited HSC activation mediated by CCR9⁺ macrophages [78], indicating that TNF α is a key cytokine in CCR9-mediated liver fibrosis.

Dendritic cells

Hepatic dendritic cells represent one fourth of the fibrotic leukocytes and TNF α dramatically induce proinflammatory and immunogenic activity of dendritic cells in liver

fibrosis [79]. Fibrotic liver-derived dendritic cells co-cultured with normal liver-derived HSCs induced various cytokines (e.g., IL-1 α , IL-6, G-CSF, GM-CSF, IL-13, LIF, and MCP-1) and chemokines (e.g., MIP-1 α , MIP-1 β , MIP-2, KC, and MIG) and TNF α blockade partially blocked the production of these cytokines and chemokines [79]. However, CD11c⁺ dendritic cells modestly activated NF- κ B in HSCs, and depletion of dendritic cells had no significant effect on BDL- and CCl₄-induced liver fibrosis [28]. This study suggests the minor role of dendritic cells in liver fibrosis.

B cells

Hepatic CD19⁺ B cells are increased in CCl₄-treated mouse livers [80]. HSC-derived retinoic acids are essential for B cell survival. B cell-deficient mice (μ MT mice) protected against CCl₄-induced liver HSC activation and fibrosis. Hepatic B cells from fibrotic mice can stimulate the production of inflammatory cytokines and chemoattractants, including TNF α . *In vivo* roles of MyD88-mediated innate immune signaling in B cells were examined by generating B cell specific-MyD88-deficient mice. After 6 weeks of CCl₄ treatment, these mice showed a significant reduction of liver fibrosis. Moreover, liver B cells from fibrotic B cell specific-MyD88-deficient mice produced less proinflammatory cytokines (e.g., TNF α). This study demonstrated that hepatic B cells can amplify the fibrogenic response by secretion of inflammatory cytokines and chemoattractants through intrinsic MyD88 signaling [80].

Clinical Implications and Conclusions

TNF α plays an important role in proinflammatory response and cell-to-cell communication. TNF signaling is closely associated with various autoimmune and inflammatory diseases. Until now, five drugs targeting TNF have been developed: infliximab, etanercept, adalimumab, golimumab, and certolizumab pegol [81]. The indications of these TNF-targeting drugs have been approved for rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, juvenile idiopathic arthritis, Crohn's disease, and ulcerative colitis [82]. Owing to the remarkable successes, the pharmaceutical industries are undergoing to develop new drugs targeting TNFR signaling, and these drugs have been tested in clinical trials in various diseases.

Liver fibrosis is a consequence of chronic liver injury and inflammation. TNF α is a key player involved in both chronic liver injury and inflammation, but the role of TNF α in liver fibrosis is complicated and the conclusions were still controversial. Recent studies have provided a better understanding of TNF α signaling in liver fibrosis. TNF α enhances HSC survival, hepatocyte death, and immune cell activation, which are associated with enhanced liver fibrosis (Figure 2). There is currently no ongoing clinical trial of TNF inhibitors for the treatment of liver fibrosis. Due to its pleiotropic effect, TNF/TNFR-targeted drugs occasionally have serious adverse events, such as lymphomas, lupus-like syndrome, and cutaneous or systemic vasculitis [82]. Importantly, the clinical trials using anti-TNF α antibody have been failed in alcoholic hepatitis [83]. Therefore, targeting of specific TNF α signaling pathways should be carefully considered as new therapeutic approach for the liver fibrosis.

Acknowledgments

Funding: This work was supported by R01 AA020172, R01 DK085252, and P42 ES010337.

REFERENCES

Papers of particular interest, published recently, have been highlighted as:

· Of importance

1. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. *Lancet*. 2014; 383:1749–1761. [PubMed: 24480518]
2. Bataller R, Brenner DA. Liver fibrosis. *J Clin Invest*. 2005; 115:209–218. [PubMed: 15690074]
This review summarized the pathological process of liver fibrosis and mechanism of fibrosis resolution, and suggested therapeutic approaches to the treatment of liver fibrosis.
3. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. *J Biol Chem*. 2000; 275:2247–2250. [PubMed: 10644669]
4. Mederacke I, Hsu CC, Troeger JS, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. *Nat Commun*. 2013; 4:2823. [PubMed: 24264436] This study employed fate-tracing technology to demonstrate that hepatic stellate cells are the major source of collagen-producing myofibroblasts.
5. Takehara T, Tatsumi T, Suzuki T, et al. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. *Gastroenterology*. 2004; 127:1189–1197. [PubMed: 15480996]
6. Vick B, Weber A, Urbanik T, et al. Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes. *Hepatology*. 2009; 49:627–636. [PubMed: 19127517]
7. Pellicoro A, Ramachandran P, Iredale JP, et al. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. *Nat Rev Immunol*. 2014; 14:181–194. [PubMed: 24566915]
8. Sudo K, Yamada Y, Moriwaki H, et al. Lack of tumor necrosis factor receptor type 1 inhibits liver fibrosis induced by carbon tetrachloride in mice. *Cytokine*. 2005; 29:236–244. [PubMed: 15760680]
9. Hernandez-Munoz I, de la Torre P, Sanchez-Alcazar JA, et al. Tumor necrosis factor alpha inhibits collagen alpha 1(I) gene expression in rat hepatic stellate cells through a G protein. *Gastroenterology*. 1997; 113:625–640. [PubMed: 9247485]
10. Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). *Microsc Res Tech*. 2000; 50:184–195. [PubMed: 10891884]
11. Grell M, Douni E, Wajant H, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. *Cell*. 1995; 83:793–802. [PubMed: 8521496]
12. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. *Cell Death Differ*. 2003; 10:45–65. [PubMed: 12655295]
13. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. *Cell*. 2003; 114:181–190. [PubMed: 12887920]
14. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. *Trends Cell Biol*. 2001; 11:372–377. [PubMed: 11514191]
15. Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. *Nat Rev Cancer*. 2010; 10:561–574. [PubMed: 20651737]
16. Ea CK, Deng L, Xia ZP, et al. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. *Mol Cell*. 2006; 22:245–257. [PubMed: 16603398]
17. Luedde T, Schwabe RF. NF-kappaB in the liver--linking injury, fibrosis and hepatocellular carcinoma. *Nat Rev Gastroenterol Hepatol*. 2011; 8:108–118. [PubMed: 21293511]
18. Hayden MS, Ghosh S. Signaling to NF-kappaB. *Genes Dev*. 2004; 18:2195–2224. [PubMed: 15371334]

19. Adhikari A, Xu M, Chen ZJ. Ubiquitin-mediated activation of TAK1 and IKK. *Oncogene*. 2007; 26:3214–3226. [PubMed: 17496917]
20. Seki E, Brenner DA, Karin M. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. *Gastroenterology*. 2012; 143:307–320. [PubMed: 22705006]
21. Liu ZG, Hsu H, Goeddel DV, et al. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. *Cell*. 1996; 87:565–576. [PubMed: 8898208]
22. Ofengeim D, Yuan J. Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death. *Nat Rev Mol Cell Biol*. 2013; 14:727–736. [PubMed: 24129419]
23. Park YH, Jeong MS, Park HH, et al. Formation of the death domain complex between FADD and RIP1 proteins in vitro. *Biochim Biophys Acta*. 2013; 1834:292–300. [PubMed: 22922561]
24. Cho YS, Challa S, Moquin D, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. *Cell*. 2009; 137:1112–1123. [PubMed: 19524513]
25. He S, Wang L, Miao L, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. *Cell*. 2009; 137:1100–1111. [PubMed: 19524512]
26. Zhang DW, Shao J, Lin J, et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. *Science*. 2009; 325:332–336. [PubMed: 19498109]
27. Jiang JX, Chen X, Fukada H, et al. Advanced glycation endproducts induce fibrogenic activity in nonalcoholic steatohepatitis by modulating TNF-alpha-converting enzyme activity in mice. *Hepatology*. 2013; 58:1339–1348. [PubMed: 23703665]
28. Pradere JP, Kluwe J, De Minicis S, et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. *Hepatology*. 2013; 58:1461–1473. [PubMed: 23553591] This paper reported that macrophage promoted survival of activated HSCs, but not HSC activation. TNF α mediated macrophage-induced NF-kB activation in HSCs.
29. Duffield JS, Forbes SJ, Constandinou CM, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. *J Clin Invest*. 2005; 115:56–65. [PubMed: 15630444]
30. Rivera CA, Bradford BU, Hunt KJ, et al. Attenuation of CCl(4)-induced hepatic fibrosis by GdCl(3) treatment or dietary glycine. *Am J Physiol Gastrointest Liver Physiol*. 2001; 281:G200–G207. [PubMed: 11408273]
31. Seki E, De Minicis S, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. *Nat Med*. 2007; 13:1324–1332. [PubMed: 17952090]
32. Tarrats N, Moles A, Morales A, et al. Critical role of tumor necrosis factor receptor 1, but not 2, in hepatic stellate cell proliferation, extracellular matrix remodeling, and liver fibrogenesis. *Hepatology*. 2011; 54:319–327. [PubMed: 21523796] This paper elucidated the contribution of TNF α signaling through TNFR1 to HSC proliferation, MMP9 expression, and liver fibrosis.
33. Simeonova PP, Gallucci RM, Hulderman T, et al. The role of tumor necrosis factor-alpha in liver toxicity, inflammation, and fibrosis induced by carbon tetrachloride. *Toxicol Appl Pharmacol*. 2001; 177:112–120. [PubMed: 11740910]
34. Kitamura K, Nakamoto Y, Akiyama M, et al. Pathogenic roles of tumor necrosis factor receptor p55-mediated signals in dimethylnitrosamine-induced murine liver fibrosis. *Lab Invest*. 2002; 82:571–583. [PubMed: 12003998]
35. Tomita K, Tamiya G, Ando S, et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. *Gut*. 2006; 55:415–424. [PubMed: 16174657]
36. Affo S, Dominguez M, Lozano JJ, et al. Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. *Gut*. 2013; 62:452–460. [PubMed: 22637703]
37. Roh YS, Song J, Seki E. TAK1 regulates hepatic cell survival and carcinogenesis. *J Gastroenterol*. 2014; 49:185–194. [PubMed: 24443058]

38. Inokuchi S, Aoyama T, Miura K, et al. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. *Proc Natl Acad Sci U S A*. 2010; 107:844–849. [PubMed: 20080763] This work described that TAK1-deficient hepatocyte showed increased susceptibility to TNF α -dependent cell death, which stimulated HSC through Kupffer cell-derived TGF β and damage-associated molecular patterns.
39. Yang L, Inokuchi S, Roh YS, et al. Transforming growth factor-beta signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1. *Gastroenterology*. 2013; 144:1042–1054. e1044. [PubMed: 23391818]
40. Massoumi R, Chmielarska K, Hennecke K, et al. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. *Cell*. 2006; 125:665–677. [PubMed: 16713561]
41. Brummelkamp TR, Nijman SM, Dirac AM, et al. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. *Nature*. 2003; 424:797–801. [PubMed: 12917690]
42. Kovalenko A, Chable-Bessia C, Cantarella G, et al. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. *Nature*. 2003; 424:801–805. [PubMed: 12917691]
43. Trompouki E, Hatzivassiliou E, Tschirritzis T, et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. *Nature*. 2003; 424:793–796. [PubMed: 12917689]
44. Reiley W, Zhang M, Sun SC. Negative regulation of JNK signaling by the tumor suppressor CYLD. *J Biol Chem*. 2004; 279:55161–55167. [PubMed: 15496400]
45. Ahmed N, Zeng M, Sinha I, et al. The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. *Nat Immunol*. 2011; 12:1176–1183. [PubMed: 22057290]
46. Trompouki E, Tsagaratou A, Kosmidis SK, et al. Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation. *Neoplasia*. 2009; 11:469–476. [PubMed: 19412431]
47. Nikolaou K, Tsagaratou A, Eftychi C, et al. Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer. *Cancer Cell*. 2012; 21:738–750. [PubMed: 22698400]
48. Urbanik T, Boger RJ, Longerich T, et al. Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice. *J Hepatol*. 2012; 57:995–1003. [PubMed: 22728872]
49. Pannem RR, Dorn C, Hellerbrand C, et al. Cylindromatosis gene CYLD regulates hepatocyte growth factor expression in hepatic stellate cells through interaction with histone deacetylase 7. *Hepatology*. 2014; 60:1066–1081. [PubMed: 24811579]
50. He F, Guo FC, Li Z, et al. Myeloid-specific disruption of recombination signal binding protein Jkappa ameliorates hepatic fibrosis by attenuating inflammation through cylindromatosis in mice. *Hepatology*. 2015; 61:303–314. [PubMed: 25145286]
51. Schwabe RF, Brenner DA. Mechanisms of Liver Injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. *Am J Physiol Gastrointest Liver Physiol*. 2006; 290:G583–G589. [PubMed: 16537970] This review discussed the pathological role of TNF α in liver injury. TNF α induces hepatocyte apoptosis and proliferation by regulation of IKK, ROS, and JNK pathways.
52. Kodama Y, Taura K, Miura K, et al. Antiapoptotic effect of c-Jun N-terminal Kinase-1 through Mcl-1 stabilization in TNF-induced hepatocyte apoptosis. *Gastroenterology*. 2009; 136:1423–1434. [PubMed: 19249395]
53. Zhao G, Hatting M, Nevzorova YA, et al. Jnk1 in murine hepatic stellate cells is a crucial mediator of liver fibrogenesis. *Gut*. 2014; 63:1159–1172. [PubMed: 24037431]
54. Hong IH, Park SJ, Goo MJ, et al. JNK1 and JNK2 regulate alpha-SMA in hepatic stellate cells during CCl4-induced fibrosis in the rat liver. *Pathol Int*. 2013; 63:483–491. [PubMed: 24134609]
55. Cubero FJ, Zhao G, Nevzorova YA, et al. Haematopoietic cell-derived Jnk1 is crucial for chronic inflammation and carcinogenesis in an experimental model of liver injury. *J Hepatol*. 2015; 62:140–149. [PubMed: 25173965]
56. Kodama Y, Kisseleva T, Iwaisako K, et al. c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. *Gastroenterology*. 2009; 137:1467–1477. e1465. [PubMed: 19549522]

57. Son G, Iimuro Y, Seki E, et al. Selective inactivation of NF-kappaB in the liver using NF-kappaB decoy suppresses CCl4-induced liver injury and fibrosis. *Am J Physiol Gastrointest Liver Physiol*. 2007; 293:G631–G639. [PubMed: 17640975]
58. Maeda S, Chang L, Li ZW, et al. IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. *Immunity*. 2003; 19:725–737. [PubMed: 14614859]
59. Geisler F, Algul H, Paxian S, et al. Genetic inactivation of RelA/p65 sensitizes adult mouse hepatocytes to TNF-induced apoptosis in vivo and in vitro. *Gastroenterology*. 2007; 132:2489–2503. [PubMed: 17570221]
60. Luedde T, Beraza N, Kotsikoris V, et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. *Cancer Cell*. 2007; 11:119–132. [PubMed: 17292824]
61. Cubero FJ, Singh A, Borkham-Kamphorst E, et al. TNFR1 determines progression of chronic liver injury in the IKKgamma/Nemo genetic model. *Cell Death Differ*. 2013; 20:1580–1592. [PubMed: 23933814] This report presents evidence for the involvement of TNFa in the progression of IKKγ/Nemo-dependent chronic liver injury. It explained the different roles of TNFR1 in hepatocytes and immune cells. Deletion of TNFR1 in hepatocytes ameliorated apoptotic cell death and liver fibrogenesis, whereas deletion in bone-marrow-derived cells accelerated chronic hepatitis.
62. Liedtke C, Bangen JM, Freimuth J, et al. Loss of caspase-8 protects mice against inflammation-related hepatocarcinogenesis but induces non-apoptotic liver injury. *Gastroenterology*. 2011; 141:2176–2187. [PubMed: 21878202]
63. Freimuth J, Bangen JM, Lambertz D, et al. Loss of caspase-8 in hepatocytes accelerates the onset of liver regeneration in mice through premature nuclear factor kappa B activation. *Hepatology*. 2013; 58:1779–1789. [PubMed: 23728913]
64. Gautheron J, Vucur M, Reisinger F, et al. A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. *EMBO Mol Med*. 2014; 6:1062–1074. [PubMed: 24963148]
65. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. *Physiol Rev*. 2008; 88:125–172. [PubMed: 18195085]
66. Saile B, Matthes N, Knittel T, et al. Transforming growth factor beta and tumor necrosis factor alpha inhibit both apoptosis and proliferation of activated rat hepatic stellate cells. *Hepatology*. 1999; 30:196–202. [PubMed: 10385656] This report discovered that the anti-apoptotic and anti-proliferative effect of TNFa in activated HSC. On the other hand, TNFa had no impact on apoptosis or proliferation in quiescent HSC.
67. Knittel T, Mehde M, Kobold D, et al. Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1. *J Hepatol*. 1999; 30:48–60. [PubMed: 9927150]
68. Osawa Y, Hoshi M, Yasuda I, et al. Tumor necrosis factor-alpha promotes cholestasis-induced liver fibrosis in the mouse through tissue inhibitor of metalloproteinase-1 production in hepatic stellate cells. *PLoS One*. 2013; 8:e65251. [PubMed: 23755201]
69. Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. *Gastroenterology*. 2014; 147:765–783. e764. [PubMed: 25046161]
70. Canbay A, Feldstein AE, Higuchi H, et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. *Hepatology*. 2003; 38:1188–1198. [PubMed: 14578857]
71. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. *Hepatology*. 2004; 39:273–278. [PubMed: 14767974]
72. Luedde T, Assmus U, Wustefeld T, et al. Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. *J Clin Invest*. 2005; 115:849–859. [PubMed: 15776110]
73. Park J, Kang W, Ryu SW, et al. Hepatitis C virus infection enhances TNFalpha-induced cell death via suppression of NF-kappaB. *Hepatology*. 2012; 56:831–840. [PubMed: 22430873]
74. Kudo H, Takahara T, Yata Y, et al. Lipopolysaccharide triggered TNF-alpha-induced hepatocyte apoptosis in a murine non-alcoholic steatohepatitis model. *J Hepatol*. 2009; 51:168–175. [PubMed: 19446916]

75. Amara S, Lopez K, Banan B, et al. Synergistic effect of pro-inflammatory TNF α and IL-17 in periostin mediated collagen deposition: potential role in liver fibrosis. *Mol Immunol*. 2015; 64:26–35. [PubMed: 25467797]
76. Moschen AR, Fritz T, Clouston AD, et al. Interleukin-32: a new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis. *Hepatology*. 2011; 53:1819–1829. [PubMed: 21381070]
77. Liu C, Tao Q, Sun M, et al. Kupffer cells are associated with apoptosis, inflammation and fibrotic effects in hepatic fibrosis in rats. *Lab Invest*. 2010; 90:1805–1816. [PubMed: 20921949]
78. Chu PS, Nakamoto N, Ebinuma H, et al. C-C motif chemokine receptor 9 positive macrophages activate hepatic stellate cells and promote liver fibrosis in mice. *Hepatology*. 2013; 58:337–350. [PubMed: 23460364]
79. Connolly MK, Bedrosian AS, Mallen-St Clair J, et al. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF- α . *J Clin Invest*. 2009; 119:3213–3225. [PubMed: 19855130]
80. Thapa M, Chinnadurai R, Velazquez VM, et al. Liver fibrosis occurs through dysregulation of MyD88-dependent innate B-cell activity. *Hepatology*. 2015; 61:2067–2079. [PubMed: 25711908]
81. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. *Blood*. 2012; 119:651–665. [PubMed: 22053109]
82. Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor signalling: live or let die. *Nat Rev Immunol*. 2015; 15:362–374. [PubMed: 26008591]
83. Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. *Hepatology*. 2004; 39:1390–1397. [PubMed: 15122768]




Figure 1. Activation of TNF signaling

TNF α binding to TNFR1 causes Complex I formation by recruitment of TRADD, RIP1, TRAF2/5, cIAP1/2, and LUBAC. cIAP1/2 promotes K63-linked polyubiquitination of RIP1, whereas A20 and CYLD deubiquitinates RIP1. In the Complex I, K63-linked polyubiquitination of RIP1 mediates TAK1-TAB1-TAB2/3 complex recruitment. TAK1 is responsible for the phosphorylation and activation of IKK complex, resulting in I κ B α degradation and NF- κ B-mediated gene transcription. Inactivation of cIAP1 or deubiquitination of RIP1 by CYLD facilitates Complex I transition to Complex II. Complex IIa consists of TRADD, RIP1, FADD and caspase-8, which induces apoptosis. Inhibition of caspase-8 or FADD causes the formation of Complex IIb, ultimately leading to necroptosis.




Figure 2. Overview of $TNF\alpha$ -mediated liver fibrosis

$TNF\alpha$ augments HSC survival, but not activation. Hepatocyte apoptosis results in the engulfment of apoptotic bodies by macrophages and HSCs. It enhances the production of death ligands (e.g., $TNF\alpha$, TRAIL and FasL) by macrophages, which further stimulates hepatocyte death. Engulfment of apoptotic bodies by HSCs increases the profibrogenic responses. $TNF\alpha$ -treated hepatocytes produce periostin, which can mediate collagen production in HSCs. HSCs also promote B cell survival. In fibrotic liver, B cells produce proinflammatory cytokines and chemoattractants (e.g., $TNF\alpha$, IL-6, MCP-1, and MIP-1 α), which can accelerate liver fibrosis.